In an attempt to control the HIV/AIDS epidemic in Thailand, the Thai government decided to bypass the patents on anti-retroviral drugs (ARVs) by issuing compulsory
A Swiss pharmaceutical company, Novartis, sought to have the January 2006 decision to reject its patent application for the cancer drug imatinib mesylate (Gleevec) reversed
In January 2006, the Patent Office of Chennai rejected the patent application by Novartis for patent of the drug Gleevec (chemically known as imatinib mesylate).
India, which followed the approach of process patenting to pharmaceuticals switched over to product patenting by way of an amendment in 2005 in order to
